Blueprint Bio Inc.

Early development of CDK2 inhibitors has been beset with tolerability problems, particularly ocular and hematological, but new data for two products suggest that headway is being made for some candida

CDK4/6 inhibitors – Eli Lilly and Company ’s Verzenio, Novartis AG ’s Kisqali and Pfizer Inc. ’s Ibrance – have proven efficacy in ER-positive/Her2-negative breast cancer, but a significant proport

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Adaptimmune, TCR² Combine Forces, Incre

It looks like biopharma industry merger and acquisition spending increased exponentially during the first quarter of 2019, with a $92bn total that outperformed Q4 2018 almost nine times over. So noted